(Q53250018)

12 May 2018

title

The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. (English)

1 reference

12 May 2018

1 reference

4

Jan Lubinski

1 reference

12 May 2018

10

Steven A Narod

1 reference

12 May 2018

Parviz Ghadirian

6

Parviz Ghadirian

1 reference

12 May 2018

Pål Møller

5

Pal Moller

1 reference

12 May 2018

Hereditary Ovarian Cancer Clinical Study Group

11

Hereditary Ovarian Cancer Clinical Study Group

1 reference

12 May 2018

Mario Beiner

1

Mario E Beiner

1 reference

12 May 2018

author name string

Amy Finch

2

1 reference

12 May 2018

Barry Rosen

3

1 reference

12 May 2018

Henry T Lynch

7

1 reference

12 May 2018

Eitan Friedman

8

1 reference

12 May 2018

Ping Sun

9

1 reference

12 May 2018

language of work or name

English

0 references

publication date

8 September 2006

1 reference

12 May 2018

published in

Gynecologic Oncology

1 reference

12 May 2018

volume

104

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

7-10

1 reference

12 May 2018

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Risk of Endometrial Carcinoma Associated with BRCA Mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Cancer Incidence in BRCA1 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

BRCA germline mutations in Jewish women with uterine serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Cancer risks in BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Association of tamoxifen and uterine sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.004

10.1016/J.YGYNO.2006.08.004

7 January 2021

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

16962648

1 reference

12 May 2018